How to Live at Peace in the Darkest Places

An FDA advisory panel voted 14 to 1 to recommend the agency remove a drug meant to prevent pre-term births from the market. McKenna was approved 11 years ago through the agency's controversial Fast Track program. A larger follow-up study showed it was no different than a placebo and has potentially serious side effects like blood clots. Separately, the CDC and the FDA greenlit Novavax's non-MRNA COVID booster.